Research Library

TriStar Technology Group LLC has had the privilege of working with innovative organizations around the world to support their research and intellectual property development over the past decade. Part of our core strategy is to also collaborate with leading platform manufacturers to generate innovative research publications.

TriStar Original and Collaborative Research

As of 2019 TriStar Technology Group has begun to actively develop our own research by collaborating with promising technology, biotechnology, and research organizations. We will continue to update this table with our new research. To view a publication simply click the "view" button on the correlated row.
wdt_ID Paper Date URL Affiliations Type
1 Multidimensional Gene Expression Models for Characterizing Response and Metastasis in Solid Tumor Samples 04/01/2019 Cofactor Genomics Poster
2 Tumor Heterogeneity and Primary Versus Metastatic Evaluation of PD-L1 04/01/2019 Istituto Oncologico del Mediterraneo Poster

Papers, Patents, and Reports That Cite TriStar

Since TriStar Technology Group's inception, we have continued to take steps to ensure that our service and product offerings come from a scientific and not a commodity point of view. We have been able to support the biomarker research efforts of many teams across the globe by continuing to provide product and service offerings that are in line with the latest trends in oncology research. In the table below you will find papers, reports, and patent applications that cite TriStar Technology Group LLC as a vendor.
wdt_ID Paper Date URL Affiliations Type
1 Inhibition of lymphatic metastasis in neuroblastoma by a novel neutralizing antibody to vascular endothelial growth factor‐D Sep-12 Chugai Pharmaceutical Co. Ltd. Paper
2 Targeting Nuclear EGFR: Strategies for Improving Cetuximab Therapy in Lung Cancer Sep-14 University of Wisconsin, U.S. Army Medical Research and Materiel Command Report
3 Anti-EpCAM antibody and uses thereof 4/4/2007 - 04/02/2028 Alfasigma SpA Patent Application
4 Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors Mar-17 AstraZeneca Paper
5 Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-Negative Breast Cancer May-14 University of Wisconsin, U.S. Army Medical Research and Materiel Command Paper
6 CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers Jul-08 Seattle Genetics, Celera Paper
7 The Discovery and Preclinical Development of ASG-5ME, an Antibody–Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer Nov-16 Agensys, Seattle Genetics Inc. Paper
8 Identification of Genes Required for the Survival of Prostate Cancer Cells Jun-11 University of Rochester U.S. Army Medical Research and Materiel Command Report
9 Immunohistochemical Detection of BRCA-1 and BRCA-2 Expression in Human Breast and Ovarian Tumors Jul-13 Merck Paper
10 pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry Nov-18 AstraZeneca, Fred Hutchinson Cancer Research Centre Paper
Inquiry Item Removed. Undo
  • No products in the cart.